Mirati Therapeutics Inc. | Ownership
Companies that own Mirati Therapeutics Inc.
venBio Select Advisor LLC
4,798,101
14.83%
400,000
9.26%
06/30/2018
Tavistock Life Sciences Co. (Investment Management)
4,701,526
14.53%
193,050
18.23%
06/30/2018
Baker Bros. Advisors LP
2,513,462
7.77%
-35,999
0.92%
06/30/2018
Fidelity Management & Research Co.
1,949,465
6.02%
763,373
0.01%
06/30/2018
Cormorant Asset Management LP
1,918,350
5.93%
0
7.66%
06/30/2018
The Vanguard Group, Inc.
1,366,063
4.22%
354,329
0%
06/30/2018
BlackRock Fund Advisors
1,350,793
4.17%
838,232
0%
06/30/2018
Deerfield Management Company LP
1,300,365
4.01%
1,103,365
2.1%
06/30/2018
Broadfin Capital LLC
1,020,178
3.15%
-423,770
7.94%
06/30/2018
SSgA Funds Management, Inc.
975,822
3.02%
278,115
0%
06/30/2018
| Address |
9393 Towne Centre Drive
San Diego California 92121
United States
|
|
Employees
|
- |
| Website |
http://www.mirati.com |
| Updated |
07/08/2019 |
| Mirati Therapeutics, Inc. is a clinical-stage oncology company, which engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA. |
